|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Modolell I, Guarner L and Malagelada JR:
Vagaries of clinical presentation of pancreatic and biliary tract
cancer. Ann Oncol. 10 Suppl 4:82–84. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiao F, Hu H, Yuan C and Wang L, Jiang W,
Jin Z, Guo Z and Wang L: Elevated expression level of long
noncoding RNA MALAT-1 facilitates cell growth, migration and
invasion in pancreatic cancer. Oncol Rep. 32:2485–2492. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maitra A and Hruban RH: Pancreatic cancer.
Annu Rev Pathol. 3:157–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moir J, White SA, French JJ, Littler P and
Manas DM: Systematic review of irreversible electroporation in the
treatment of advanced pancreatic cancer. Eur J Surg Oncol.
40:1598–1604. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burkey MD, Feirman S, Wang H, Choudhury
SR, Grover S and Johnston FM: The association between smokeless
tobacco use and pancreatic adenocarcinoma: A systematic review.
Cancer Epidemiol. 38:647–653. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fan Y, Shi C, Li T and Kuang T:
MicroRNA-454 shows anti-angiogenic and anti-metastatic activity in
pancreatic ductal adenocarcinoma by targeting LRP6. Am J Cancer
Res. 7:139–147. 2017.PubMed/NCBI
|
|
10
|
Zhang G, Ai D, Yang X, Ji S, Wang Z and
Feng S: MicroRNA-610 inhibits tumor growth of melanoma by targeting
LRP6. Oncotarget. 8:97361–97370. 2017.PubMed/NCBI
|
|
11
|
Jin Y, Tao LP, Yao SC, Huang QK, Chen ZF,
Sun YJ and Jin SQ: MicroRNA-582-5p suppressed gastric cancer cell
proliferation via targeting AKT3. Eur Rev Med Pharmacol Sci.
21:5112–5120. 2017.PubMed/NCBI
|
|
12
|
Wang X and Wu X: The Role of
MicroRNA-1207-5p in colorectal cancer. Clin Lab. 63:1875–1882.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang D, Du G, Xu A, Xi X and Li D:
Expression of miR-149-3p inhibits proliferation, migration, and
invasion of bladder cancer by targeting S100A4. Am J Cancer Res.
7:2209–2219. 2017.PubMed/NCBI
|
|
14
|
Liu S, Liu K, Zhang W, Wang Y, Jin Z, Jia
B and Liu Y: miR-449a inhibits proliferation and invasion by
regulating ADAM10 in hepatocellular carcinoma. Am J Transl Res.
8:2609–2619. 2016.PubMed/NCBI
|
|
15
|
Cheng RF, Wang J, Zhang JY, Sun L, Zhao
YR, Qiu ZQ, Sun BC and Sun Y: MicroRNA-506 is up-regulated in the
development of pancreatic ductal adenocarcinoma and is associated
with attenuated disease progression. Chin J Cancer. 35:642016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tu MJ, Pan YZ, Qiu JX, Kim EJ and Yu AM:
MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic
cancer cell proliferation and tumorigenesis. Oncotarget.
7:45547–45561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wen D, Li S, Jiang W, Zhu J, Liu J and
Zhao S: miR-539 inhibits human colorectal cancer progression by
targeting RUNX2. Biomed Pharmacother. 95:1314–1320. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quan J, Qu J and Zhou L: MicroRNA-539
inhibits glioma cell proliferation and invasion by targeting
DIXDC1. Biomed Pharmacother. 93:746–753. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li S, Yang F, Wang M, Cao W and Yang Z:
miR-378 functions as an onco-miRNA by targeting the
ST7L/Wnt/β-catenin pathway in cervical cancer. Int J Mol Med.
40:1047–1056. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu JW, Wang TX, You L, Zheng LF, Shu H,
Zhang TP and Zhao YP: Insulin-like growth factor 1 receptor
(IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated
with TNM stage of pancreatic cancer. PLoS One. 9:e928472014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hirakawa T, Yashiro M, Murata A, Hirata K,
Kimura K, Amano R, Yamada N, Nakata B and Hirakawa K: IGF-1
receptor and IGF binding protein-3 might predict prognosis of
patients with resectable pancreatic cancer. BMC Cancer. 13:3922013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Subramani R, Lopez-Valdez R, Arumugam A,
Nandy S, Boopalan T and Lakshmanaswamy R: Targeting insulin-like
growth factor 1 receptor inhibits pancreatic cancer growth and
metastasis. PLoS One. 9:e970162014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng D, Golubovskaya V, Kurenova E, Wood
C, Massoll NA, Ostrov D, Cance WG and Hochwald SN: A novel strategy
to inhibit FAK and IGF-1R decreases growth of pancreatic cancer
xenografts. Mol Carcinog. 49:200–209. 2010.PubMed/NCBI
|
|
25
|
Farhana L, Dawson MI, Murshed F, Das JK,
Rishi AK and Fontana JA: Upregulation of miR-150* and miR-630
induces apoptosis in pancreatic cancer cells by targeting IGF-1R.
PLoS One. 8:e610152013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tian X, Hao K, Qin C, Xie K, Xie X and
Yang Y: Insulin-like growth factor 1 receptor promotes the growth
and chemoresistance of pancreatic cancer. Dig Dis Sci.
58:2705–2712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moser C, Schachtschneider P, Lang SA,
Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK and
Stoeltzing O: Inhibition of insulin-like growth factor-I receptor
(IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor,
reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J
Cancer. 44:1577–1586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qadir MI and Faheem A: miRNA: A diagnostic
and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene
Expr. 27:197–204. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang S, Gong X, Zhang G, Huang G, Lu Y
and Li Y: MicroRNA-140 regulates cell growth and invasion in
pancreatic duct adenocarcinoma by targeting iASPP. Acta Biochim
Biophys Sin (Shanghai). 48:174–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Keklikoglou I, Hosaka K, Bender C, Bott A,
Koerner C, Mitra D, Will R, Woerner A, Muenstermann E1, Wilhelm H,
et al: MicroRNA-206 functions as a pleiotropic modulator of cell
proliferation, invasion and lymphangiogenesis in pancreatic
adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene.
34:4867–4878. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu C, Zhou R, Zhou Q, Chang Y and Jiang
M: microRNA-539 suppresses tumor growth and tumorigenesis and
overcomes arsenic trioxide resistance in hepatocellular carcinoma.
Life Sci. 166:34–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Y, Hong W, Zhou C, Jiang Z, Wang G,
Wei G and Li X: miR-539 inhibits FSCN1 expression and suppresses
hepatocellular carcinoma migration and invasion. Oncol Rep.
37:2593–2602. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang H, Li S, Yang X, Qiao B, Zhang Z and
Xu Y: miR-539 inhibits prostate cancer progression by directly
targeting SPAG5. J Exp Clin Cancer Res. 35:602016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lv LY, Wang YZ, Zhang Q, Zang HR and Wang
XJ: miR-539 induces cell cycle arrest in nasopharyngeal carcinoma
by targeting cyclin-dependent kinase 4. Cell Biochem Funct.
33:534–540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jin H and Wang W: MicroRNA-539 suppresses
osteosarcoma cell invasion and migration in vitro and targeting
Matrix metallopeptidase-8. Int J Clin Exp Pathol. 8:8075–8082.
2015.PubMed/NCBI
|
|
36
|
Gu L and Sun W: MiR-539 inhibits thyroid
cancer cell migration and invasion by directly targeting CARMA1.
Biochem Biophys Res Commun. 464:1128–1133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu Q, Gong JP, Li J, Zhong SL, Chen WX,
Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH and Tang JH: Down-regulation
of miRNA-452 is associated with adriamycin-resistance in breast
cancer cells. Asian Pac J Cancer Prev. 15:5137–5142. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
An Y, Cai L, Wang Y, Zhu D, Guan Y and
Zheng J: Onkologie. Onkologie. 32:638–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
E C, Li J, Shao D, Zhang D, Pan Y, Chen L
and Zhang X: The insulin-like growth factor-I receptor inhibitor
picropodophyllin-induced selective apoptosis of hepatocellular
carcinoma cell through a caspase-dependent mitochondrial pathway.
Oncol Res. 21:103–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sichani MM, Yazdi FS, Moghaddam NA,
Chehrei A, Kabiri M, Naeimi A and Taheri D: Prognostic value of
insulin-like growth factor-I receptor expression in renal cell
carcinoma. Saudi J Kidney Dis Transpl. 21:69–74. 2010.PubMed/NCBI
|
|
41
|
Zhao S, Qiu Z, He J, Li L and Li W:
Insulin-like growth factor receptor 1 (IGF1R) expression and
survival in non-small cell lung cancer patients: A meta-analysis.
Int J Clin Exp Pathol. 7:6694–6704. 2014.PubMed/NCBI
|
|
42
|
Gryko M, Kiśluk J, Cepowicz D, Zińczuk J,
Kamocki Z, Guzińska-Ustymowicz K, Pryczynicz A, Czyżewska J, Kemona
A and Kędra B: Expression of insulin-like growth factor receptor
type 1 correlate with lymphatic metastases in human gastric cancer.
Pol J Pathol. 65:135–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xie QX, Lin XC, Zhang MF, Han CX and Guo
YH: Expression of IGF-I and IGF-IR in bladder cancer. Ai Zheng.
23:707–709. 2004.(In Chinese). PubMed/NCBI
|
